Child and Adolescent Psychiatric Clinics of North America
Treatment-Resistant Depression in Adolescents: Recognition and Management
Section snippets
Treatment-resistant depression
The term “treatment-resistant depression” is defined to mean lack of response to adequate treatment. There is recognition that treatment resistance exists on a continuum as a function of the number and type of treatments one has received, but much of the extant literature refers to patients who fail to respond to even one adequate trial as treatment resistant [2], [3]. An adequate response in the clinical trial literature has been defined most often as “much” or “very much” improvement on the
Rates of treatment response in selective serotonin reuptake inhibitors and psychotherapy trials
Examining all clinical trials that involved SSRIs, the initial clinical response rate is approximately 60%, which means that approximately 40% of participants are partial- or nonresponders or would be defined as having treatment-resistant depression [23]. The rate of symptomatic remission (being symptom free) at 8 to 12 weeks is much lower—approximately 30% to 40% [24], [25]. Naturalistic treatment studies suggest that the proportion of patients who achieve clinical remission increases with
Demographics
Some studies have reported that younger children respond as well to SSRIs as adolescents [24], whereas other studies have shown a better response in adolescents than in children [33]. Adolescents also seem to metabolize SSRIs more rapidly than do adults, with much shorter steady-state half-lives found for paroxetine, sertraline, and citalopram [34], [35], [36]. Higher doses or twice-a-day dosing may be required for some adolescents. A second developmental difference compared with adults is the
Document improvement or the lack thereof
Patients who have been chronically depressed often have difficulty judging improvement unless assessment is anchored to concrete markers and symptoms, which is aided by the use of standardized assessments, such as the CDRS-R [5], or the self-report scales, such as the Children's Depression Inventory [67], Beck Depression Inventory [68], Mood and Feelings Questionnaire [69], [70], Center for Epidemiologic Studies-Depression Scale [71], and the Reynolds Adolescent Depression Scale [72]. A patient
Addressing co-occurring health risk behaviors and contextual factors
Several intercorrelated health risk behaviors that co-occur with depression often are not addressed or even assessed in typical clinical trials [63], [140], [141]. A frequently overlooked source of morbidity in depressed adolescents is persistent sleep difficulties. From a developmental point of view, the average adolescent needs more sleep and gets less sleep than younger children [142]. On top of this developmental sleep deficit, depressed adolescents have sleep disruption, and SSRIs can
Summary and recommendations for further research
How can we use this information to improve the outcome of depressed adolescents? First, for an optimal response, one must promote and ensure adherence and use an adequate dose of medication or psychotherapy given for an adequate duration. Psychoeducation that promotes parental and child hopefulness in the context of realistic expectation about treatment may be helpful in improving adherence, and outcome. Proper assessment of psychiatric and medical comorbidity and environmental factors
References (152)
- et al.
Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications
Clin Psychol Rev
(1998) - et al.
Treatment resistant depression: methodological overview and operational criteria
Eur Neuropsychopharmacol
(1999) - et al.
Cognitive-behavioral group treatment of adolescent depression: efficacy of acute group treatment and booster sessions
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Cognitive behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence based medicine review
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Cognitive-behavioral treatment for depressed adolescents
Behav Ther
(1990) - et al.
Paroxetine pharmacokinetics in depressed children and adolescents
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Age may affect response to antidepressants with serotonergic and noradrenergic actions
J Affect Disord
(2003) - et al.
Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled study
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Cognitive-behavioral group treatment of adolescent depression: prediction of outcome
Behav Ther
(1992)
Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up
J Am Acad Child Adolesc Psychiatry
Outcome at 6 months for 50 adolescents with major depression treated in a health maintenance organization
J Am Acad Child Adolesc Psychiatry
Impact of comorbidity on a cognitive-behavioral group treatment for adolescent depression
J Am Acad Child Adolesc Psychiatry
Pilot evaluation of the coping course: a cognitive-behavioral intervention to enhance coping skills incarcerated youth
J Am Acad Child Adolesc Psychiatry
An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder
J Am Acad Child Adolesc Psychiatry
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
Neuropsychopharmacology
Platelet serotonin transporter in depressed children and adolescents: 3H-paroxetine platelet binding before and after sertraline
J Am Acad Child Adolesc Psychiatry
Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy
J Am Acad Child Adolesc Psychiatry
Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine
J Am Acad Child Adolesc Psychiatry
Factors protecting against the development of adjustment difficulties in young adults exposed to childhood sexual abuse
Child Abuse Negl
Validity of the shortened mood and feelings questionnaire in a community sample of children and adolescents: a preliminary research note
Psychiatry Res
Screening for anxiety and depression in early adolescence
J Am Acad Child Adolesc Psychiatry
Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder
J Am Acad Child Adolesc Psychiatry
Predicting the one-year course of adolescent major depression
J Am Acad Child Adolesc Psychiatry
Treatment guidelines for children and adolescents with bipolar disorder
J Am Acad Child Adolesc Psychiatry
Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: a randomized trial of group cognitive intervention
J Am Acad Child Adolesc Psychiatry
Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients
J Am Acad Child Adolesc Psychiatry
Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study
J Am Acad Child Adolesc Psychiatry
Work Group on Quality Issues. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders
J Am Acad Child Adolesc Psychiatry
The Texas children's medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder
J Am Acad Child Adolesc Psychiatry
Achieving remission and managing relapse in depression
J Clin Psychiatry
Clinical global improvement scale: assessment manual of psychopharmacology
Children's depression rating scale, revised
Psychopharmacol Bull
Fluoxetine in child and adolescent depression: acute and maintenance treatment
Depress Anxiety
Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
Am J Psychiatry
Fluoxetine 40–60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10–20 mg: a pilot study
J Child Adolesc Psychopharmacol
The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients
Ann Clin Psychiatry
Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design
Depress Anxiety
Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis
Depress Anxiety
Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients
Psychopharmacology
Is there a relationship between clinical efficacy and antidepressant dosage in major depression?
Encephale
Effect of increasing the dose and duration of sertraline trial in the treatment of depressed nursing home residents
J Geriatr Psychiatry Neurol
Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response
Acta Psychiatr Scand
Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day
Encephale
Serum disposition of sertraline, n-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression
Hum Psychopharmacol
Paroxetine in major depression: correlating plasma concentrations and clinical response
Pharmacopsychiatry
Dose-response relationship of recent antidepressants in the short-term treatment of depression
Dialogues Clin Neurosci
Efficacy of interpersonal psychotherapy for depressed adolescents
Arch Gen Psychiatry
A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive treatments
Arch Gen Psychiatry
Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders
J Child Psychol Psychiatry
Cited by (21)
Treatment-resistant depression in children and adolescents
2023, Progress in Brain ResearchDecreased response inhibition to sad faces during explicit and implicit tasks in females with depression: Evidence from an event-related potential study
2017, Psychiatry Research - NeuroimagingCitation Excerpt :Depression is one of the most common psychiatric disorders and a leading cause of disability worldwide (Goodwin et al., 2006). Studies suggest that at least 20% of adolescents experience a depressive episode before adulthood, which is associated with high morbidity and mortality (Brent and Birmaher, 2006). Women show a younger age of onset and higher rate of recurrence of depression than men (Kessler et al., 2005; Schuch et al., 2014).
Depression in Children and Adolescents
2016, Systems Neuroscience in DepressionAnnual Research Review: Defining and treating pediatric treatment-resistant depression
2020, Journal of Child Psychology and Psychiatry and Allied DisciplinesDistinguishing Bipolar Depression from Unipolar Depression in Youth: Preliminary Findings
2017, Journal of Child and Adolescent Psychopharmacology
This work was supported by NIMH grants P30 MH66371 and U01 MH61835.